This report was first published by Endpoints News. To see the original version, click here
Earlier this year, the Belgian cell therapy startup EsoBiotec had only 12 employees and had raised €22 million to develop a cutting-edge infusion that turns a patient’s immune cells into destroyers of disease.
But despite its meager resources, EsoBiotec managed to do something that its better-capitalized peers hadn’t: It became the first to report clinical data on a highly-anticipated cancer treatment called an in vivo CAR-T therapy.
您已閱讀7%（526字），剩余93%（7268字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。